On 6 June 2025, the SCCS published the preliminary opinion on the safety of prostaglandin analogues in cosmetic products. The prostaglandin analogues taken into consideration are Methylamido-Dihydro-Noralfaprostal (MDN) with (CAS No. 155206-01-2), Isopropyl Cloprostenate (IPCP) with (CAS No. 157283-66-4), and Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) with (CAS No. 1185851-52-8).
This content is only available to Premium Members.
Get access to all our Premium content and services.
Start your Free Trial or Discover our plans.
Already a Premium member? Sign In
